At the Preclinical Departure of Scanomed Ltd hybrid imaging technologies combining the modern equipment of radiology and nuclear medicine play an important role in both the translational research process and clinical diagnostics. With the help of the preclinical non-invasive in vivo molecular imaging systems the drug developing process can be shortened and its costs can be reduced. Moreover, by using of these imaging modalities we can get acquainted with the biochemical and pathobiochemical processes that are essential for understanding and treating diseases, or map the behavior of a new drug candidate. At our laboratory a broad range of imaging technologies and animal models are available for the evaluation of tissue structure, organ function, and molecular interactions.
In vivo imaging of small and large laboratory animals (e.g.: rats, mice, rabbit, pig, cat and dog) have emerged as a critical component of preclinical biomedical research. Animal imaging provides a noninvasive means of assaying biological structure and function in vivo. Importantly, thanks to its noninvasive nature, imaging allows serial assay of animal models of cancer (by e.g.: syngeneic and xenogeneic models), neurological, cardiovascular and other diseases from the disease inception to progression and monitoring of the effectiveness of treatments. The aim in preclinical molecular imaging studies is the investigation of the biodistribution and targeting of specific radiolabeled (with a diagnostic or therapeutic radionuclide) molecules in experimental animal models by modern dedicated small animal imaging devices, such as nanoScan PET/MRI or nanoScan SPECT/CT.